LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD: RESULTS OF A PHASE II PROSPECTIVE TRIAL

被引：0
|
作者：
Wang, Y. [1 ]
Chang, Y. -J. [1 ]
Huang, X. -J. [1 ]
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1517
引用
收藏
页码：618 / 619
页数：2
相关论文
共 50 条
  • [1] Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes
    Wang, Yu
    Chang, Ying-Jun
    Chen, Lu
    Xu, Lan-Ping
    Bian, Zhi-Lei
    Zhang, Xiao-Hui
    Yan, Chen-Hua
    Liu, Kai-Yan
    Huang, Xiao-Jun
    ONCOIMMUNOLOGY, 2017, 6 (11):
  • [2] G-CSF primed HLA haploidentical transplantation from maternal or collateral donor using ATG plus reduced dose of posttransplantation cyclophosphamide: Results of a phase II prospective trial
    Wang, Y.
    Huang, X-J
    BONE MARROW TRANSPLANTATION, 2017, 52 : S489 - S489
  • [3] Increased Efficacy of Chemomobilization with Intermediate Dose Cytarabine plus G-CSF Compared to G-CSF Alone for Patients with Multiple Myeloma: Results of a Prospective, Randomized Trial
    Czerw, Tomasz
    Mendrek, Wlodzimierz
    Najda, Jacek
    Sobczyk-Kruszelnicka, Malgorzata
    Sadus-Wojciechowska, Maria
    Soska, Katarzyna
    Glowala-Kosinska, Magdalena
    Chwieduk, Agata
    Fidyk, Wojciech
    Holowiecki, Jerzy
    Giebel, Sebastian
    BLOOD, 2016, 128 (22)
  • [4] Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients
    Ma, Xiaodi
    Xu, Zhengli
    Han, Tingting
    Zhang, Yuanyuan
    Han, Wei
    Fu, Haixia
    Zhang, Xiaohui
    Lin, Fan
    Huang, Xiaojun
    Xu, Lanping
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] Results of a BNLI randomized trial of G-CSF dose after cyclophosphamide 1.5g/m2 for progenitor cell mobilization.
    Ings, SJ
    Schey, S
    Hancock, B
    Watts, MJ
    Vandenberghe, E
    Goldstone, AH
    Elston, T
    Pettengell, R
    Long, S
    Smith, P
    Linch, DC
    BLOOD, 1999, 94 (10) : 666A - 666A
  • [6] High-dose chemotherapy (HDCT) with G-CSF support before radiotherapy (RT) in malignant gliomas (MG):: Phase II trial
    Viñolas, N
    Gil, M
    Verger, E
    Villá, S
    Pujol, T
    Caral, L
    García, M
    Graus, F
    Estapé, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S120 - S120
  • [7] Ancestim (SCF) and high-dose twice-daily filgrastim (G-CSF) is superior to G-CSF alone or cyclophosphamide plus G-CSF for mobilization of peripheral blood stem cells (PBSC) in patients with indolent lymphoproliferative disorders previously treated with fludarabine; Results of a historically-controlled Phase-II study.
    Seymour, John Francis
    Morgan, Sue
    Prince, Miles
    Westerman, David Alan
    Wolf, Max M.
    Carney, Dennis A.
    Yuen, Kally
    BLOOD, 2006, 108 (11) : 873A - 873A
  • [8] Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results
    Arun, Banu K.
    Dhinghra, Kapil
    Valero, Vicente
    Kau, Shu-Wan
    Broglio, Kristine
    Booser, Daniel
    Guerra, Laura
    Yin, Guosheng
    Walters, Ronald
    Sahin, Aysegul
    Ibrahim, Nuhad
    Buzdar, Aman U.
    Frye, Debbie
    Sneige, Nour
    Strom, Eric
    Ross, Merrick
    Theriault, Richard L.
    Vadhan-Raj, Saroj
    Hortobagyi, Gabriel N.
    ONCOLOGIST, 2011, 16 (11): : 1527 - 1534
  • [9] Sequential interleukin-3 (IL-3) & granulocyte-colony stimulating factor (G-CSF) priming of high dose etoposide (VP) and cyclophosphamide (CY): A phase I/II trial.
    Bernstein, SH
    Fay, JW
    Christiansen, N
    Pinero, L
    Herzig, R
    Herzig, G
    BLOOD, 1995, 86 (10) : 2737 - 2737
  • [10] Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients
    P Quittet
    P Ceballos
    E Lopez
    Z Y Lu
    P Latry
    C Becht
    E Legouffe
    N Fegueux
    C Exbrayat
    D Pouessel
    V Rouillé
    J P Daures
    B Klein
    J F Rossi
    Bone Marrow Transplantation, 2006, 38 : 275 - 284
12345